As India enters the third COVID-19 wave, the anti-viral drug Molnupiravir was quickly launched for use in mild-moderate illness with a high risk of progressing to severe disease. There is however skepticism about its efficacy in real-life situations.
What is the experience of those who used it first hand? Is there any real-life data on its use, especially from countries already gone through a third wave?